High ligand efficiency quinazoline compounds as novel A2A adenosine receptor antagonists

Fluorescence Emissive Fluorinated Pyrimido[5,4-h]quinazolines: Synthesis, Structure, and Photophysical and Halochromic Properties

Planar tricyclic aromatics and azaheteroaromatics are of significant interest to organic chemists in the field of materials science owing to their excellent photoconductivity, electroluminescence and fluorescence properties enabled by their rigid extended π-conjugation. Furthermore, tricyclic azaheteroaromatics are effective ligands for organometallic catalysis and a prominent drug discovery framework. Herein, we present the first one-step synthesis of a less-accessible tricyclic fluorophore comprising a 5,6-difluoro-2,9-diarylpyrimido[5,4-h]quinazoline core entailing the regiospecific tandem condensation of tetrafluoroterephthalonitrile and derivatives of benzamidine hydrochloride in the presence of potassium carbonate or cesium carbonate under mild conditions. Single-crystal X-ray diffractometry studies confirmed the structure of the 5,6-difluoro-2,9-diarylpyrimido[5,4-h]quinazolines, and various interactions such as π-π stacking. Spectroscopic measurements, including ultraviolet-visible (UV-vis) and fluorescence spectroscopy, of the synthesized pyrimido[5,4-h]quinazolines revealed that they have excellent fluorescence properties both in the solution and solid states, displaying red-shifted maximum fluorescence wavelengths in the solid state compared to those in the solution state. Density functional theory (DFT) calculations and electrochemical analyses revealed that the introduction of an electron-withdrawing group, such as a halogen, stabilized the energy levels. Thermogravimetric (TG) analysis indicated high decomposition temperatures for 5,6-difluoro-2,9-diarylpyrimido[5,4-h]quinazolines, confirming their favorable thermal stability. Finally, the halochromism of 5,6-difluoro-2,9-diarylpyrimido[5,4-h]quinazolines arising from the protonation of the amino group and/or pyrimidine backbone is described.

Synthesis of 4-tosyl quinazoline derivatives with the assistance of ultrasound irradiation as a guide to the reaction pathway

In this study, we tried to show the role of ultrasonic waves in the reaction pathway of quinazolines with an amide functional group. At first, 4-tosyl quinazolines were prepared using a simple, rapid, and one-pot reaction of Cu-catalyzed cross-coupling reactions of 2-iodoaniline and tosyl methyl isocyanide (TosMIC) in THF solvent under ultrasonic conditions in 30 min with good efficiency. The role of ultrasound in this reaction is to reduce the time and increase the efficiency of product preparation. Then, considering the potential of some synthesized derivatives to carry out the cross-coupling reaction with the help of isocyanides, copper iodide catalyst, and cesium carbonate as a base in THF solvent was investigated. Spectroscopic evidence1H-NMR,13C-NMR, IR, and Mass) shows interesting results that the reaction proceeds under ultrasonic conditions towards C-H activation and without the use of ultrasonic towards cross-coupling reaction. Finally, 22 new heterocyclic compounds from the 4-tosylquinazoline family have been synthesized under ultrasonic conditions in this project with a simple, rapid, and efficient method.

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

The adenosine A2A receptor (A2AR) has been identified as a therapeutic target for treating neurodegenerative diseases and cancer. In recent years, we have highlighted the 2-aminoquinazoline heterocycle as an promising scaffold for designing new A2AR antagonists, exemplified by 6-bromo-4-(furan-2-yl)quinazolin-2-amine 1 (Ki (hA2AR) = 20 nM). Here, we report the synthesis of new 2-aminoquinazoline derivatives with substitutions at the C6- and C7-positions, and the introduction of aminoalkyl chains containing tertiary amines at the C2-position to enhance antagonist activity and solubility properties. Compound 5m showed a high affinity for hA2AR with a Ki value of 5 nM and demonstrated antagonist activity with an IC50 of 6 µM in a cyclic AMP assay. Introducing aminopentylpiperidine and 4-[(piperidin-1-yl)methyl]aniline substituents maintained the binding affinities (9x, Ki = 21 nM; 10d, Ki = 15 nM) and functional antagonist activities (9x, IC50 = 9 µM; 10d, IC50 = 5 µM) of the synthesized compounds while improving solubility. This study provides insights into the future development of A2AR antagonists for therapeutic applications.

Computational Workflow for Refining AlphaFold Models in Drug Design Using Kinetic and Thermodynamic Binding Calculations: A Case Study for the Unresolved Inactive Human Adenosine A3 Receptor

A structure-based drug design pipeline that considers both thermodynamic and kinetic binding data of ligands against a receptor will enable the computational design of improved drug molecules. For unresolved GPCR-ligand complexes, a workflow that can apply both thermodynamic and kinetic binding data in combination with alpha-fold (AF)-derived or other homology models and experimentally resolved binding modes of relevant ligands in GPCR-homologs needs to be tested. Here, as test case, we studied a congeneric set of ligands that bind to a structurally unresolved G protein-coupled receptor (GPCR), the inactive human adenosine A3 receptor (hA3R). We tested three available homology models from which two have been generated from experimental structures of hA1R or hA2AR and one model was a multistate alphafold 2 (AF2)-derived model. We applied alchemical calculations with thermodynamic integration coupled with molecular dynamics (TI/MD) simulations to calculate the experimental relative binding free energies and residence time (τ)-random accelerated MD (τ-RAMD) simulations to calculate the relative residence times (RTs) for antagonists. While the TI/MD calculations produced, for the three homology models, good Pearson correlation coefficients, correspondingly, r = 0.74, 0.62, and 0.67 and mean unsigned error (mue) values of 0.94, 1.31, and 0.81 kcal mol-1, the τ-RAMD method showed r = 0.92 and 0.52 for the first two models but failed to produce accurate results for the multistate AF2-derived model. With subsequent optimization of the AF2-derived model by reorientation of the side chain of R1735.34 located in the extracellular loop 2 (EL2) that blocked ligand's unbinding, the computational model showed r = 0.84 for kinetic data and improved performance for thermodynamic data (r = 0.81, mue = 0.56 kcal mol-1). Overall, after refining the multistate AF2 model with physics-based tools, we were able to show a strong correlation between predicted and experimental ligand relative residence times and affinities, achieving a level of accuracy comparable to an experimental structure. The computational workflow used can be applied to other receptors, helping to rank candidate drugs in a congeneric series and enabling the prioritization of leads with stronger binding affinities and longer residence times.

The Mystery of EVP4593: Perspectives of the Quinazoline-Derived Compound in the Treatment of Huntington's Disease and Other Human Pathologies

Quinazoline derivatives have various pharmacological activities and are widely used in clinical practice. Here, we reviewed the proposed mechanisms of the physiological activity of the quinazoline derivative EVP4593 and perspectives for its clinical implication. We summarized the accumulated data about EVP4593 and focused on its activities in different models of Huntington's disease (HD), including patient-specific iPSCs-based neurons. To make a deeper insight into its neuroprotective role in HD treatment, we discussed the ability of EVP4593 to modulate calcium signaling and reduce the level of the huntingtin protein. Moreover, we described possible protective effects of EVP4593 in other pathologies, such as oncology, cardiovascular diseases and parasite invasion. We hope that comprehensive analyses of the molecular mechanisms of EVP4593 activity will allow for the expansion of the scope of the EVP4593 application.